ImmTOR® and ImmTOR-IL™
Potential to transform the lives of patients with developmental therapies designed to overcome autoimmunity and immunogenicity by restoring natural immune system balance in vivo.
What are ImmTOR® and ImmTOR‑IL™?
Selecta Biosciences’ precision immune tolerance platform is designed to give rise to antigen-specific immune tolerance.
ImmTOR® and ImmTOR‑IL™ have the potential to mitigate unwanted immune responses to autoantigens, gene therapy vectors and therapeutic biologics.
The Science Behind ImmTOR® and ImmTOR-IL™
Leveraging the human immune system to generate precision immune tolerance in vivo
Unwanted immune responses can cause autoimmune disease, prevent the redosing of life saving gene therapy and compromise the efficacy and safety of biologic therapy.
Controlled, scalable manufacturing
The universal formulation of ImmTOR® is able to be produced at a commercial scale via a well-controlled and scalable manufacturing process.
Selecta has developed a commercial-scale, Good Manufacturing Practice (GMP), process to ensure that ImmTOR® is consistently produced and controlled according to quality standards.
The tolerogenic activity of ImmTOR® has been reproduced in multiple independent laboratories using a range of biologic therapies and immunogenic antigens, indicating the platform’s ability to mitigate unwanted immune responses. Selecta’s research has been published in multiple high-level peer-reviewed journals including Nature Nanotechnology, Nature Communications, Science Advances and Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Partnerships
Join our growing group of partnerships to leverage the potential of ImmTOR® and further advance your therapy
Our ImmTOR® platform has exciting potential across a broad range of therapeutic areas. Learn more about our partnerships and partnering opportunities.








Building on the Success of SEL-212
Our ImmTOR® platform is being evaluated in an ongoing Phase 3 clinical trial.
With a Phase 3 clinical program in chronic refractory gout that has been strategically licensed to Swedish Orphan Biovitrum AB (Sobi), Selecta’s ImmTOR® platform is being developed to mitigate the immunogenicity of a fungal-derived enzyme. Additionally, ImmTOR® was observed to effectively mitigate formation of anti-AAV capsids in a Phase 1 safety trial. Selecta intends to build upon these early results by developing ImmTOR® to restore self-tolerance in autoimmune disease and in combination with gene therapy and other biologic therapy to create a pipeline of precision immune tolerance therapies.
Our Pipeline
Advancing a growing and diversified wholly owned and partnered pipeline
With our clinically validated ImmTOR® platform, we intend to advance new precision immune tolerance therapies through development. Dig deep into our pipeline of wholly owned and partnered ImmTOR®-driven therapies.
